

06/10/2019

Nikolaos Megkoulas, PhD Chief Executive Officer QualiMetrix SA 579 Mesogeion Avenue Athens, Agia Paraskevi 15343 Greece Office of Pharmaceutical Quality Operations Division 1 10 Waterview Blvd, 3rd Floor Parsippany, NJ 07054

Reference: Inspection Date(s): 4/22/2019 - 4/23/2019

Location: QualiMetrix SA

579 Mesogeion Avenue

Athens, Agia Paraskevi 15343 Greece

FEI: 3015131309

Dear Dr. Megkoulas:

We are enclosing a copy of the establishment inspection report (EIR) for the inspection that the U.S. Food and Drug Administration (FDA) conducted at your premises on the referenced locale and date(s). When the Agency concludes that an inspection is "closed" under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment. This procedure is applicable to EIRs for inspections completed on or after April 1, 1997.

The Agency continually works to make its regulatory process and activities more transparent to the regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Valerie L. Whipp via telephone at 240-402-2599 or email at Valerie. Whipp@fda.hhs.gov.

For more information on the U.S. FDA, please visit our website at www.fda.gov.

Sincerely,

Valerie L. Whipp - Digitally signed by Valerie L. Whipp -S DN: c-US, o-US. Government, ou-HHS, ou-FDA, ou-People, 0.9.2342, 19200300.100.1.1=1300072724 on-Valerie L. Whipp -S

Valerie L. Whipp Supervisory Consumer Safety Officer Investigations Branch II Division I, OPQO

Enclosure: Establishment Inspection Report (EIR)

U.S. Food and Drug Administration

www.fda.gov